Nivolumab is a type of protein designed to attach to a certain type of white blood cells called the T cells. T cells are part of the immune system needed to attack the cancer. Nivolumab acts to improve the activity of T cells, thereby increasing the ability of the immune system to kill cancer cells. Ipilimumab is another type of protein that acts in a different way to increase the activity of T cells. If licenced, nivolumab in combination with ipilimumab will offer additional treatment option to prolong lives of this patient group.
Nivolumab (Opdivo) with ipilimumab (Yervoy) for recurrent, metastatic, squamous cell head and neck cancer – first line
